This article first appeared on GuruFocus. Humacyte Inc (NASDAQ:HUMA) is set to release its Q4 2025 earnings on Mar 27, 2026.
Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results ...
DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today ...
Humacyte launched Symvess™ for extremity vascular trauma, achieving $517,000 in Q1 revenue and raising $46.7 million. Symvess is an acellular tissue engineered vessel, indicated for urgent ...
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial ...
Humacyte Inc (NASDAQ:HUMA) shares are tumbling in Tuesday’s after-hours session after the company announced a proposed public offering. What Happened: After the market close on Tuesday, Humacyte said ...
Humacyte will announce Q1 2025 financial results and provide corporate updates on May 13, 2025, at 8:30 AM ET. Humacyte, Inc. will announce its financial results for the first quarter of 2025 on May ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results